Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.

Bullboard (GREY:IMVIF)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by Breakthorough1on Jul 28, 2023 3:31pm

RE:RE:2002 Q2 Results

The results. They should disclose the results the have now, even if they are winding down the trials/company. Their only chance to leave this story with dignity.
57
Discussion
Comment by Jthom376on Jul 28, 2023 8:28am

RE:2002 Q2 Results

This company did nothing but lie to investors... It's hard to believe companies are allowed to conduct business like this. Hard to believe that the people running it can't be held personally ...more  
104
Discussion
Post by Breakthorough1on Jul 28, 2023 4:46am

2002 Q2 Results

"Where we sit today -- and I think Brittany covered it nicely in the scripted part of the presentation -- we know that we can get through our milestones that we believe are value creating with ...more  
165
Discussion
Post by Breakthorough1on Jul 27, 2023 3:39pm

March 16 2023 (D)

"And Brandon, just to sort of get to the center of the question, we are getting very positive feedback on the data from strategics from academics, from people that are close to the field. The ...more  
95
Comment by Breakthorough1on Jul 27, 2023 3:22pm

RE:FTI'S QUALIFICATION TO ACT AS MONITOR-March 30

Section 9 of the Pre-Filing Report of the Monitor: "On March 30, 2023, the IMV Group engaged FTI to assist it in understanding its strategic options and to prepare, on a contingency basis ...more  
68
Discussion
Post by Breakthorough1on Jul 27, 2023 3:16pm

FTI'S QUALIFICATION TO ACT AS MONITOR-March 30

FIT was engaged to assist IMV as early as the 30th of March, following the documents of the CCAA Proceedings.
88
Discussion
Post by Breakthorough1on Jul 27, 2023 3:13pm

March 16 2023 (C)

We now do the math, obviously, from completing enrollment shortly plus the time to complete the first scans that will have a good look at the data that we will be able to, I guess, submit into late ...more  
91
Post by Breakthorough1on Jul 27, 2023 1:54pm

March 16 2023 (B)

"The first answer of the question with respect to supply of what we’re now considering is going to be commercial product. We’re very well evolved. We actually switched our CDMO in the 2022 ...more  
88
Post by Breakthorough1on Jul 27, 2023 1:53pm

March 16 2023

"We’re in a situation where the drug is actually working, and we want to make sure it gets to market, not just for patients and not just for the better therapies for cancer, but for IMV ...more  
94
Post by Breakthorough1on Jul 27, 2023 1:49pm

January 10 2022

"The study is designed to be Stage 1 is, Does pembrolizumab plus (IMV’s) mavero equal better (results) than just pembro? And if it goes forward into Stage 2, the deal originally was ...more  
79
Post by Breakthorough1on Jul 27, 2023 1:45pm

January 13 2022

"We believe this study should help affirm and extend our understanding of the clinical benefit previously seen in r/r DLBCL patients in the SPiReL trial and may support the use of PD-L1 as a ...more  
79
Post by Breakthorough1on Jul 27, 2023 1:39pm

December 28 2020

Has anyone seen this data?: “We are encouraged by the data generated thus far. Results are consistent with the mechanism of action of our DPX delivery platform demonstrated across prior clinical ...more  
84
Comment by Breakthorough1on Jul 27, 2023 1:15pm

RE:RE:Publication of SPiReL data and class action

Is this is the rumor, we should collect all the misleading statements and initiate a class action. They are any: - Announcements related to COVID Vaccine resukts which never came. - Announcements ...more  
82
Discussion
Comment by Sandinistaon Jul 27, 2023 1:10pm

RE:Publication of SPiReL data and class action

Of course it works. Rumor is IMV is being sold for 3-5 million, it's probably worth 300-500 million, or more. And on top of that, creditors get compensated in the sale, followed by IMV employees ...more  
121
Discussion
Post by Breakthorough1on Jul 27, 2023 6:05am

Publication of SPiReL data and class action

 SPiReL data have just been published in a journal. In the population CD20+/PDL-1+, 56% of the total of patients, it gives:     ORR: 46%    DCR: 77%     ...more  
169
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities